| Hormone refractory prostate cancer
Nubeqa vs Provenge
Side-by-side clinical, coverage, and cost comparison for hormone refractory prostate cancer.Deep comparison between: Nubeqa vs Provenge with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsProvenge has a higher rate of injection site reactions vs Nubeqa based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Provenge but not Nubeqa, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Nubeqa
Provenge
At A Glance
Oral
Twice daily
Androgen receptor inhibitor
IV infusion
Every 2 weeks
Autologous cellular immunotherapy
Indications
- Hormone refractory prostate cancer
- Metastatic Castration-Sensitive Prostate Carcinoma
- Hormone refractory prostate cancer
Dosing
Hormone refractory prostate cancer 600 mg (two 300 mg tablets) orally twice daily with food; continue until disease progression or unacceptable toxicity.
Metastatic Castration-Sensitive Prostate Carcinoma 600 mg (two 300 mg tablets) orally twice daily with food; when used with docetaxel for mCSPC, administer first of 6 cycles of docetaxel within 6 weeks of starting NUBEQA; continue NUBEQA until disease progression or unacceptable toxicity.
Hormone refractory prostate cancer 3 complete doses at approximately 2-week intervals; each dose infused IV over approximately 60 minutes; premedicate with acetaminophen and antihistamine approximately 30 minutes prior to infusion.
Contraindications
—
—
Adverse Reactions
Most common (>=10%) Increased AST, decreased neutrophil count, increased bilirubin, fatigue, increased ALT (nmCRPC and mCSPC); constipation, rash, decreased appetite, hemorrhage, increased weight, hypertension (mCSPC with docetaxel).
Serious Febrile neutropenia (6%), decreased neutrophil count (2.8%), musculoskeletal pain (2.6%), pneumonia (2.6%), urinary retention, hematuria, arrhythmias, spinal cord compression, ischemic heart disease, heart failure.
Postmarketing COVID-19/COVID-19 pneumonia, myocardial infarction, sudden death, seizures, drug-induced liver injury.
Most common (>=15%) Chills, fatigue, fever, back pain, nausea, joint ache, headache
Serious Acute infusion reactions, cerebrovascular events, eosinophilia, rhabdomyolysis, myasthenia gravis, myositis, tumor flare
Postmarketing Syncope, transient ischemic attack, strokes, hypotension, myocardial infarction, deep venous thrombosis, pulmonary embolism
Pharmacology
Darolutamide is an androgen receptor (AR) inhibitor that competitively inhibits androgen binding, AR nuclear translocation, and AR-mediated transcription. The major metabolite ketodarolutamide exhibits similar in vitro activity and decreased prostate cancer cell proliferation in vitro and tumor volume in xenograft models.
PROVENGE is an autologous cellular immunotherapy designed to induce an immune response targeted against prostatic acid phosphatase (PAP), an antigen expressed in most prostate cancers; APCs are activated ex vivo with the PAP-GM-CSF fusion protein, take up and process the recombinant antigen, and display it on the cell surface to stimulate T cell and antibody responses.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Nubeqa
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (0/12) · Qty limit (11/12)
Provenge
- Covered on 5 commercial plans
- PA (1/12) · Step Therapy (0/12) · Qty limit (0/12)
UnitedHealthcare
Nubeqa
- Covered on 4 commercial plans
- PA (8/8) · Step Therapy (0/8) · Qty limit (7/8)
Provenge
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Nubeqa
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Provenge
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAssistance Fund: Prostate Cancer
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAssistance Fund: Prostate Cancer
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
NubeqaView full Nubeqa profile
ProvengeView full Provenge profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.